The investment formalizes and deepens the existing collaboration between CDT and Sarborg, which has already supported the evaluation of CDT's clinical assets through Sarborg's proprietary signature analysis and artificial intelligence capabilities. Sarborg's business is built on the principle that biological, chemical and industrial signatures can function as a universal data language to identify, interpret and generate high-value opportunities. By analyzing, matching and learning from large-scale signature datasets, Sarborg generates ranked, data-driven outputs that inform scientific and commercial decision making.
CDT believes that acquiring a stake in Sarborg enhances strategic alignment between the two businesses and provides shareholders with increased growth opportunities. Sarborg has developed a proprietary intellectual property portfolio that includes solid-form and cocrystal assets, together with signature-based analytical capabilities. Both companies share a focus on solid-form development, creating clear scientific and commercial synergies and the potential for complementary asset strategies over time.
The transaction provides CDT shareholders with exposure to a growing business whose activities extend beyond pharmaceuticals into additional sectors where signature analysis can be applied. CDT believes this broader participation offers the opportunity to benefit from Sarborg's continued expansion while maintaining a focused approach to advancing CDT's own asset portfolio.
"Our collaboration with Sarborg has already demonstrated the value of data-driven, signature-led analysis in evaluating and identifying opportunities across our portfolio," said Dr. Andrew Regan, Chief Executive of CDT. "By acquiring a significant stake in Sarborg, we are strengthening ...
